Source: Journal of clinical oncology. Unidade: FM
Subjects: BIOMARCADORES, FÍGADO (LESÕES;FISIOPATOLOGIA), HEPATOPATIAS (FISIOPATOLOGIA;ETIOLOGIA;COMPLICAÇÕES), MEDICAMENTO (EFEITOS ADVERSOS)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OVERMAN, Michael J et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. Journal of clinical oncology, v. 28, n. 14, p. 2549-2555, 2011Tradução . . Disponível em: https://doi.org/10.1200/JCO.2009.27.5701. Acesso em: 09 maio 2024.APA
Overman, M. J., Maru, D. M., Charnsangavej, C., Loyer, E. M., Wang, H., Oathak, P., et al. (2011). Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. Journal of clinical oncology, 28( 14), 2549-2555. doi:10.1200/JCO.2009.27.5701NLM
Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Oathak P, Eng C, Hoff PMG, Vauthey J-N, Wolff R a, Kopetz S. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury [Internet]. Journal of clinical oncology. 2011 ; 28( 14): 2549-2555.[citado 2024 maio 09 ] Available from: https://doi.org/10.1200/JCO.2009.27.5701Vancouver
Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Oathak P, Eng C, Hoff PMG, Vauthey J-N, Wolff R a, Kopetz S. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury [Internet]. Journal of clinical oncology. 2011 ; 28( 14): 2549-2555.[citado 2024 maio 09 ] Available from: https://doi.org/10.1200/JCO.2009.27.5701